2021 国际多学科共识声明：射频消融及相关超声引导消融技术治疗良恶性甲状腺疾病

2021-12-23 美国头颈学会 Head Neck

超声引导下消融治疗甲状腺良恶性疾病越来越受关注，本文主要针对射频消融及相关超声引导消融技术治疗良恶性甲状腺疾病提供共识指导。内容涉及术前评估、技术、术后管理、疗效和潜在并发症等方面。

中文标题：

英文标题：

Radiofrequency ablation and related ultrasound-guided ablation technologies for treatment of benign and malignant thyroid disease: An international multidisciplinary consensus statement

发布机构：

美国头颈学会

发布日期：

2021-12-23

简要介绍：

超声引导下消融治疗甲状腺良恶性疾病越来越受关注，本文主要针对射频消融及相关超声引导消融技术治疗良恶性甲状腺疾病提供共识指导。内容涉及术前评估、技术、术后管理、疗效和潜在并发症等方面。

相关资料下载：

GetToolGuiderByIdResponse(projectId=1, id=b5f2e1c002301320, title=2021 国际多学科共识声明：射频消融及相关超声引导消融技术治疗良恶性甲状腺疾病, enTitle=Radiofrequency ablation and related ultrasound-guided ablation technologies for treatment of benign and malignant thyroid disease: An international multidisciplinary consensus statement, guiderFrom=Head Neck, authorId=0, author=, summary=超声引导下消融治疗甲状腺良恶性疾病越来越受关注，本文主要针对射频消融及相关超声引导消融技术治疗良恶性甲状腺疾病提供共识指导。内容涉及术前评估、技术、术后管理、疗效和潜在并发症等方面。, cover=https://img.medsci.cn/20211224/1640354191097_1608702.jpg, journalId=0, articlesId=null, associationId=1307, associationName=美国头颈学会, associationIntro=, copyright=0, guiderPublishedTime=Thu Dec 23 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">超声引导下消融治疗甲状腺良恶性疾病越来越受关注，本文主要针对射频消融及相关超声引导消融技术治疗良恶性甲状腺疾病提供共识指导。内容涉及术前评估、技术、术后管理、疗效和潜在并发症等方面。</span></p>, tagList=[TagDto(tagId=666, tagName=射频消融), TagDto(tagId=3313, tagName=甲状腺疾病)], categoryList=[CategoryDto(categoryId=6, categoryName=内分泌, tenant=100), CategoryDto(categoryId=40, categoryName=影像放射, tenant=100), CategoryDto(categoryId=73, categoryName=头颈外科, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=666, guiderKeyword=射频消融, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=1, guiderRegion=10, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=4043, appHits=164, showAppHits=0, pcHits=962, showPcHits=3879, likes=0, shares=28, comments=10, approvalStatus=1, publishedTime=Fri Dec 24 21:50:41 CST 2021, publishedTimeString=2021-12-23, pcVisible=1, appVisible=1, editorId=1608702, editor=dajiong, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=2, createdBy=null, createdName=dajiong, createdTime=Fri Dec 24 22:02:34 CST 2021, updatedBy=1608702, updatedName=dajiong, updatedTime=Sat Jan 06 22:19:06 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=2021 国际多学科共识声明：射频消融及相关超声引导消融技术治疗良恶性甲状腺疾病 (1).pdf)])

2021 国际多学科共识声明：射频消融及相关超声引导消融技术治疗良恶性甲状腺疾病 (1).pdf

下载请点击：

评论区 (9)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1230128, encodeId=15c31230128e4, content=赞赞赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03f58224280, createdName=ms1000001349037147, createdTime=Sat Jul 02 13:17:28 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084504, encodeId=0fb3108450477, content=👍👍赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210816/d6f733f1d88b4a3eacb17c6ae60fee1e/60bac44ce944447294ee076bcbedc201.jpg, createdBy=d4935293116, createdName=李娜3724, createdTime=Sun Dec 26 22:36:58 CST 2021, time=2021-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206134, encodeId=f27b1206134dc, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e24e5619067, createdName=ms5000000063737375, createdTime=Sat Mar 26 16:30:20 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185446, encodeId=11e31185446c8, content=👌, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8c25597134, createdName=ms6000000807686529, createdTime=Tue Jan 18 03:36:41 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179593, encodeId=b3cf11e9593cb, content=实用 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Jan 01 20:03:47 CST 2022, time=2022-01-01, status=1, ipAttribution=)]
2022-07-02 ms1000001349037147

赞赞赞

90 0
[GetPortalCommentsPageByObjectIdResponse(id=1230128, encodeId=15c31230128e4, content=赞赞赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03f58224280, createdName=ms1000001349037147, createdTime=Sat Jul 02 13:17:28 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084504, encodeId=0fb3108450477, content=👍👍赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210816/d6f733f1d88b4a3eacb17c6ae60fee1e/60bac44ce944447294ee076bcbedc201.jpg, createdBy=d4935293116, createdName=李娜3724, createdTime=Sun Dec 26 22:36:58 CST 2021, time=2021-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206134, encodeId=f27b1206134dc, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e24e5619067, createdName=ms5000000063737375, createdTime=Sat Mar 26 16:30:20 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185446, encodeId=11e31185446c8, content=👌, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8c25597134, createdName=ms6000000807686529, createdTime=Tue Jan 18 03:36:41 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179593, encodeId=b3cf11e9593cb, content=实用 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Jan 01 20:03:47 CST 2022, time=2022-01-01, status=1, ipAttribution=)]
2021-12-26 李娜3724

👍👍赞

110 1

展开1条回复
[GetPortalCommentsPageByObjectIdResponse(id=1230128, encodeId=15c31230128e4, content=赞赞赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03f58224280, createdName=ms1000001349037147, createdTime=Sat Jul 02 13:17:28 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084504, encodeId=0fb3108450477, content=👍👍赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210816/d6f733f1d88b4a3eacb17c6ae60fee1e/60bac44ce944447294ee076bcbedc201.jpg, createdBy=d4935293116, createdName=李娜3724, createdTime=Sun Dec 26 22:36:58 CST 2021, time=2021-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206134, encodeId=f27b1206134dc, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e24e5619067, createdName=ms5000000063737375, createdTime=Sat Mar 26 16:30:20 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185446, encodeId=11e31185446c8, content=👌, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8c25597134, createdName=ms6000000807686529, createdTime=Tue Jan 18 03:36:41 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179593, encodeId=b3cf11e9593cb, content=实用 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Jan 01 20:03:47 CST 2022, time=2022-01-01, status=1, ipAttribution=)]
2022-03-26 ms5000000063737375

好

87 0
[GetPortalCommentsPageByObjectIdResponse(id=1230128, encodeId=15c31230128e4, content=赞赞赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03f58224280, createdName=ms1000001349037147, createdTime=Sat Jul 02 13:17:28 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084504, encodeId=0fb3108450477, content=👍👍赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210816/d6f733f1d88b4a3eacb17c6ae60fee1e/60bac44ce944447294ee076bcbedc201.jpg, createdBy=d4935293116, createdName=李娜3724, createdTime=Sun Dec 26 22:36:58 CST 2021, time=2021-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206134, encodeId=f27b1206134dc, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e24e5619067, createdName=ms5000000063737375, createdTime=Sat Mar 26 16:30:20 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185446, encodeId=11e31185446c8, content=👌, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8c25597134, createdName=ms6000000807686529, createdTime=Tue Jan 18 03:36:41 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179593, encodeId=b3cf11e9593cb, content=实用 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Jan 01 20:03:47 CST 2022, time=2022-01-01, status=1, ipAttribution=)]
2022-01-18 ms6000000807686529

👌

87 0
[GetPortalCommentsPageByObjectIdResponse(id=1230128, encodeId=15c31230128e4, content=赞赞赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=90, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=03f58224280, createdName=ms1000001349037147, createdTime=Sat Jul 02 13:17:28 CST 2022, time=2022-07-02, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1084504, encodeId=0fb3108450477, content=👍👍赞, beContent=null, objectType=guider, channel=null, level=null, likeNumber=110, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210816/d6f733f1d88b4a3eacb17c6ae60fee1e/60bac44ce944447294ee076bcbedc201.jpg, createdBy=d4935293116, createdName=李娜3724, createdTime=Sun Dec 26 22:36:58 CST 2021, time=2021-12-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1206134, encodeId=f27b1206134dc, content=好, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e24e5619067, createdName=ms5000000063737375, createdTime=Sat Mar 26 16:30:20 CST 2022, time=2022-03-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1185446, encodeId=11e31185446c8, content=👌, beContent=null, objectType=guider, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=c8c25597134, createdName=ms6000000807686529, createdTime=Tue Jan 18 03:36:41 CST 2022, time=2022-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1179593, encodeId=b3cf11e9593cb, content=实用 , beContent=null, objectType=guider, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d25a5516768, createdName=一己怀, createdTime=Sat Jan 01 20:03:47 CST 2022, time=2022-01-01, status=1, ipAttribution=)]
2022-01-01 一己怀

实用

94 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

内分泌指南

2021 国际多学科共识声明：射频消融及相关超声引导消融技术治疗良恶性甲状腺疾病

相关指南

拓展阅读

科室

工具

服务